Dr. Phillips on Activity With Acalabrutinib Plus Bendamustine/Rituximab in MCL
Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.
Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses safety and efficacy findings for acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma (MCL) during the 2018 ASH Annual Meeting.
Efficacy rates, especially in the treatment-naive population, were impressive, with complete response rates greater than 70%. The combination was also deemed to be relatively safe, Phillips says, with adverse events similar between the treatment-naive and relapsed/refractory groups.
